Study on clinical effect of Novonorm on treating type 2 diabetic patients with atherosclerosis

VernacularTitle:诺和龙治疗2型糖尿病合并动脉粥样硬化患者的疗效观察
Author: Hanbei CHEN ; Yi LIU ; Xiaoyong LI
Publication Type:Journal Article
Keywords: Novonorm; Type 2 diabetes; Atherosclerosis
From: Clinical Medicine of China 2010;26(11):1187-1189
CountryChina
Language:Chinese
Abstract: Objective To assess the clinical effect of Novonorm on treating type 2 diabetic patients with atherosclerosis. Methods Sixty-five patients of type 2 diabetes with atherosclerosis were randomly divided into 2 groups :36 patients took Novonorm,and the other 29 individuals were treated with Glipizide. The blood glucose and CIMT were compared before and after treatment for 12 months. Results The postprandial blood glucose decreased by(1.99 ± 1.06)mmol/L after the treatment of Novonorm,which was significantly higher than that of(0. 99 ±0. 54)mmol/L after the treatment of Glipizide(P ＜ 0. 05). CIMT significantly decreased from (1.11 ± 0. 07)mm before treatment to(1.02 ± 0. 08)mm after treatment in the Novonorm group(P ＜ 0. 05),whereas CIMT were similar between after and before treatment in the Glipizide group(1.07 ± 0. 06)mm vs.(1.10 ± 0. 08)mm(P ＞ 0. 05).Conclusions Novonorm is a kind of effective and safe regent,which can be used to treat type 2 diabetic patients with atherosclerosis.